Lessons from dolutegravir and neural tube defects

Lancet HIV. 2021 Jan;8(1):e3-e4. doi: 10.1016/S2352-3018(20)30280-0.

Authors

Elaine Abrams¹, Landon Myer²

Affiliations

¹ ICAP, Mailman School of Public Health and Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. Electronic address: eja1@columbia.edu.
² Division of Epidemiology and Biostatistics and Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

PMID: 33387476
DOI: 10.1016/S2352-3018(20)30280-0

No abstract available

Publication types

Letter

MeSH terms

Brazil
Female
HIV Integrase Inhibitors / adverse effects*
Heterocyclic Compounds, 3-Ring / adverse effects*
Humans
Neural Tube Defects / etiology*
Oxazines / adverse effects*
Piperazines / adverse effects*
Pregnancy
Pyridones / adverse effects*

Substances

HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir